Stock Events

Stock Events

Aurinia Pharmaceuticals 

C$22.40
142
+C$0.34+1.54% Tuesday 15:28

Statistics

Day High
22.4
Day Low
21.95
52W High
27.04
52W Low
15.46
Volume
438.3
Avg. Volume
-
Mkt Cap
2.98B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.02
0.08
0.18
0.28
Expected EPS
0.22
Actual EPS
N/A

Financials

100.73%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
393.25MRevenue
396.1MNet Income

Analyst Ratings

17.46Average Price Target
The highest estimate is 17.46.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0UJF.LSE. It's not an investment recommendation.
Apple
29
AAPL
Amazon
26
AMZN
AMD
26
AMD
Tesla
25
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline develops treatments in areas similar to Aurinia, including autoimmune diseases, making them a direct competitor.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie competes in the immunology space, offering drugs that could be alternatives to Aurinia's products.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a broad portfolio that includes treatments for autoimmune diseases, directly competing with Aurinia's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb has a strong presence in the immunology and oncology sectors, areas where Aurinia is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on novel therapeutics in areas including inflammation, which overlaps with Aurinia's focus on autoimmune diseases.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the autoimmune disease market.
Novartis
NVS
Mkt Cap304.1B
Novartis offers a range of treatments for autoimmune diseases, competing with Aurinia's lupus nephritis treatment.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a focus on inflammatory and respiratory diseases, making it a competitor in the autoimmune treatment market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diverse portfolio that includes treatments for lupus, directly competing with Aurinia's lupus nephritis drug.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, develops medications for autoimmune diseases, including lupus, making it a competitor.

About

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Show more...
CEO
Kevin C. Tang
Employees
128
Country
Canada
ISIN
CA05156V1022
WKN
000A1W7D4

Listings

STU
DE
IKAP.STU
MU
DE
IKAP.MU
LSE
GB
0UJF.LSE
F
DE
IKAP.F

0 Comments

Share your thoughts

FAQ

What is Aurinia Pharmaceuticals stock price today?▼
The current price of 0UJF.LSE is C$22.40 CAD — it has increased by +1.54% in the past 24 hours. Watch Aurinia Pharmaceuticals stock price performance more closely on the chart.
What is Aurinia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Aurinia Pharmaceuticals stocks are traded under the ticker 0UJF.LSE.
Is Aurinia Pharmaceuticals stock price growing?▼
0UJF.LSE stock has fallen by -1.4% compared to the previous week, the month change is a +1.74% rise, over the last year Aurinia Pharmaceuticals has showed a +31.89% increase.
What is Aurinia Pharmaceuticals market cap?▼
Today Aurinia Pharmaceuticals has the market capitalization of 2.98B
When is the next Aurinia Pharmaceuticals earnings date?▼
Aurinia Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Aurinia Pharmaceuticals earnings last quarter?▼
0UJF.LSE earnings for the last quarter are 0.39 CAD per share, whereas the estimation was 0.34 CAD resulting in a +16.67% surprise. The estimated earnings for the next quarter are N/A CAD per share.
What is Aurinia Pharmaceuticals revenue for the last year?▼
Aurinia Pharmaceuticals revenue for the last year amounts to 393.25M CAD.
What is Aurinia Pharmaceuticals net income for the last year?▼
0UJF.LSE net income for the last year is 396.1M CAD.
How many employees does Aurinia Pharmaceuticals have?▼
As of September 09, 2026, the company has 128 employees.
In which sector is Aurinia Pharmaceuticals located?▼
Aurinia Pharmaceuticals operates in the Health & Wellness sector.
When did Aurinia Pharmaceuticals complete a stock split?▼
Aurinia Pharmaceuticals has not had any recent stock splits.
Where is Aurinia Pharmaceuticals headquartered?▼
Aurinia Pharmaceuticals is headquartered in EDMONTON, Canada.